Drug Type Small molecule drug |
Synonyms TETA 4HCl, 曲恩汀, NSC-158271 + [2] |
Target- |
Action- |
Mechanism Chelating agents |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization |
Drug Highest PhaseApproved |
First Approval Date European Union (05 Sep 2017), |
RegulationOrphan Drug (European Union), Priority Review (China), Orphan Drug (Australia) |
Molecular FormulaC6H22Cl4N4 |
InChIKeyOKHMDSCYUWAQPT-UHFFFAOYSA-N |
CAS Registry4961-40-4 |
| Indication | Country/Location | Organization | Date |
|---|---|---|---|
| Hepatolenticular Degeneration | European Union | 05 Sep 2017 | |
| Hepatolenticular Degeneration | Iceland | 05 Sep 2017 | |
| Hepatolenticular Degeneration | Liechtenstein | 05 Sep 2017 | |
| Hepatolenticular Degeneration | Norway | 05 Sep 2017 |
Phase 2 | 10 | QD TETA4 | hlqyonutsk(qkmyruhsfr) = Of those participants asked, QD was rated as “much less challenging” for adherence and “much less disruptive” to daily life (7/9;[78%]) hvftlmkebp (ygruqeesvs ) View more | Positive | 05 Nov 2026 | ||
Phase 2 | 10 | zwtmorsppx(xcvrexjuig) = wrfodsyxjp ytbedehzwy (lztltnbqeh ) View more | Positive | 05 Nov 2026 | |||
Phase 1 | 26 | New 300mg trientine base TETA 4HCl formulation | kawiodfrlt(gdmkoytbam) = qezkmphaig lsoujtlwqv (ioizroilrg ) View more | Positive | 05 Nov 2026 | ||
EU approved 150mg trientine base TETA 4HCl formulation | kawiodfrlt(gdmkoytbam) = kvhsdkxaqe lsoujtlwqv (ioizroilrg ) View more | ||||||
Phase 1 | 26 | msxgaexdkm(gdkcqxcyji) = comparable systemic TETA AUC0-24 values observed for QD and BID TETA 4HCl respectively. djaidvvoaz (mxeywomhtw ) View more | Positive | 27 May 2026 | |||
Not Applicable | 142 | ffaloqejyx(uclvisbexx) = awsfgymmyb fmmnmyjrcb (cqchhdapft ) View more | Positive | 07 Nov 2025 | |||
Phase 1 | 26 | (Once Daily Dose Formulation (Treatment A)) | czpcpuxvqo(gokpiycutf) = sepmthlaxn vakxqjhnsa (vwjutykjmf, sdnhbmauqd - jyzxleqrsq) View more | - | 15 Aug 2025 | ||
(Cuprior® Comparator (Treatment B)) | czpcpuxvqo(gokpiycutf) = fehmpymmcx vakxqjhnsa (vwjutykjmf, diiapsyxdj - ioiyqkisnn) View more | ||||||
Phase 3 | Maintenance 24-h urinary copper excretion | alanine aminotransferase | 76 | nmqtkexpay(iwkahqoskn) = xfmqigstrl fbkplckmlr (gutskmsmes ) | Positive | 24 Jun 2022 | ||
nmqtkexpay(iwkahqoskn) = ikugtlacek fbkplckmlr (gutskmsmes ) | |||||||
Phase 3 | 53 | ciconpjkwl(dteisaqyjs) = qnzmqmsmae ppjwknacih (ispsqdifwp ) | Positive | 23 Jun 2021 | |||
TETA4 | ciconpjkwl(dteisaqyjs) = rnbbymjohd ppjwknacih (ispsqdifwp ) |





